CC BY-NC-ND 4.0 · Geburtshilfe Frauenheilkd 2020; 80(04): 399-409
DOI: 10.1055/a-1126-4247
GebFra Science
Review/Übersicht
Georg Thieme Verlag KG Stuttgart · New York

Use of Taxanes in Metastatic HER2-negative Breast Cancer – a Status Report

Article in several languages: English | deutsch
Oleg Gluz
1  Westdeutsche Studiengruppe, Mönchengladbach, Germany
2  Ev. Krankenhaus Bethesda, Brustzentrum Niederrhein, Mönchengladbach, Germany
3  Uniklinik Köln, Köln, Germany
,
Cornelia Kolberg-Liedtke
4  Charité – Universitätsmedizin Berlin, Frauenklinik, Berlin, Germany
,
Frederik Marmé
5  Universitätsklinikum Mannheim, Frauenklinik, Mannheim, Germany
,
Marc Thill
6  Agaplesion Markus Krankenhaus, Klinik für Gynäkologie, Frankfurt am Main, Germany
› Author Affiliations
Further Information

Publication History

received 08 August 2019
revised 20 January 2020

accepted 21 February 2020

Publication Date:
21 April 2020 (online)

  

Abstract

The most important goal of treatment of patients with metastatic breast cancer is maintenance or even improvement of quality of life. In this setting, chemotherapy should be used with as much restraint as possible. If palliative chemotherapy is indicated, the taxane drug class is an established treatment option. The updated guidelines of the Gynaecological Oncology Working Group (AGO), Breast Committee, of the German Society for Gynaecology and Obstetrics (DGGG) and the German Cancer Society e. V. (DKG) provide recommendations with the greatest possible evidence on which of the licensed taxanes can be used in which treatment situation in the metastatic setting.